Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selegiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | SNCA | P37840 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | PKM | P14618 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selegiline SCHEMBL473659 | 1.00 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL12248117 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL22232 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL1286950 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL5499736 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL74753 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL15867136 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL7105217 | 0.95 | MAOB (0.93) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL1171497 | 0.95 | MAOB (0.93) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL4611911 | 0.93 | MAOB (0.90) | MAOBMAOAMAPK1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5294 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250329454-A1 | DIAGNOSTIC INDICES FOR NEURODEGENERATIVE CONDITIONS | CHASE THERAPEUTICS CORP (US) | 2025-10-23 | — | — | US | claimed |
| EP-4608388-A1 | COMBINATORIAL, AND ROTATIONAL COMBINATORIAL THERAPIES FOR OBESITY AND OTHER DISEASES | STARROCK PHARMA INC. (US) | 2025-09-03 | — | — | EP | claimed |
| CN-119790152-A | Treatment of neurological disorders using modulators of UNC13A gene transcripts | 奎里斯公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119522282-A | Splice transducer antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-25 | — | — | CN | claimed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | claimed |
| CN-119452086-A | GAPMER antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-14 | — | — | CN | claimed |
| US-20250051766-A1 | TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS | QURALIS CORPORATION | 2025-02-13 | — | — | US | claimed |
| CN-119390634-A | Selegiline hydrochloride ring-opening impurity and preparation method and application thereof | 安徽贝克制药股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0643578-A1 | A NEW COMPOSITION CONTAINING SELEGILINE | ORION-YHTYMÄ OY (FI) | 1995-03-22 | — | — | EP | claimed |
| EP-0527835-B1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORP (US) | 1994-10-26 | — | — | EP | claimed |
| WO-1994022435-A1 | A NEW COMPOSITION CONTAINING SELEGILINE | Orion-Yhtymä Oy (FI) | 1994-10-13 | — | — | WO | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| EP-0344675-A2 | Method for the production of selegiline hydrochloride | FARMAKON (CS) | 1989-12-06 | — | — | EP | claimed |